紫杉醇与泌尿系肿瘤化疗研究进展
摘要
紫杉醇(paclitaxel)是国际上继阿霉素和含铂类抗癌药之后最热点的抗肿瘤新药,其独特的作用机制和抗癌活性一直备受肿瘤医学界的关注,美国FDA已批准紫杉醇用于转移性卵巢癌和乳腺癌的相对治疗.
出处
《现代泌尿外科杂志》
CAS
2002年第3期184-186,共3页
Journal of Modern Urology
参考文献21
-
1Halder S,Chintapalli J,Croce CM. Taxol induces Bcl- 2 phosphorylation and death of prostate cancer cells. Cancer Res,1996,56(5) :1253 - 1255.
-
2Blagosklonny MV,Schulte T, Nguyen P, et al. Taxol - induced apoptosis and phosphorylation of Bcl - 2 protein involves C - Raf - l and represents a novel C - Raf - l signal transduction pathway. Cancer Res, 1995, 56(8): 1851 - 1854.
-
3Blagosklonny MV, Schulte T, Nguyen P, et al. Taxol induction of p21WAF1 and p53 requires C- Raf- l. Cancer Res,1995, 55(20) :4623 -4626.
-
4Sagata N,Watanable N, Vande GF, et al. The C - Mos proto - oncogene product is a cytostatic factor responsible for mitotic arrest in vertebrate eggs. Nature,1998, 342(6249) :512 - 518.
-
5Jordan MA,Wendell K,Gardiner S,et al. Mitotic block induced in hela cells by low concentrations of paclitaxel results in abnormal mitotic exit and apoptotic cell death. Cancer Res, 1996,56(4) :814 - 825.
-
6Guinan P, Shaw M, Mirochnik Y, et al. paclitaxel is more effective than thalidomide in inhibiting LNCaP tumor growth in a prostate cancer model.Methods Find Exp Clin Pharmacol, 1998,20(9):739- 742.
-
7Reinecke P,Schmitz M,Schneider EM, et al. Multidrug resistance pbenotype and paclitaxel(Taxol)sensitivity in human renal carcinoma cell lines of different histologic types. Cancer Invest,2000, 18(7) :614 - 625.
-
8Yvon AM, Wadsworth P, Jordan MA. Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell ,1999, 10(4) :947- 959.
-
9Walpole ET, Dutcher JP, Sparano J, et al. Survival after phase Ⅱ treatment of advanced renal cell carcinoma with taxol or high - dose interleukin - 2. J Immunother, 1993,13(4) :275 - 281.
-
10Au JL, Kalns J, Gan Y,et al. phamcologic effects of paclitaxel in human bladder tumors. Cancer Chemother Pharmacol,1997, 41(1):69-74.
-
1范丽琼,彭燕,孙厚斌.奥沙利铂联合氟尿嘧啶和亚叶酸钙治疗晚期大肠癌临床观察[J].中国煤炭工业医学杂志,2008,11(4):505-506. 被引量：3
-
2陆洪炳.三维适形放疗联合奈达铂治疗中晚期食管癌的临床研究[J].实用临床医药杂志,2015,19(23):141-142. 被引量：4
-
3覃运荣,姚清深,李致文,俸小平,苏贞栋,黄羽.奥沙利铂对大肠癌化疗敏感性的实验观察[J].中国肿瘤临床与康复,2007,14(2):106-107. 被引量：3
-
4李宁,杨卫兵.奥沙利铂联合CF/5-Fu治疗晚期大肠癌疗效观察[J].贵州医药,2005,29(9):804-805. 被引量：2
-
5刘松定,宫福花,桑建峰.羟基喜树碱联合铂类抗癌药治疗晚期消化道肿瘤[J].河南职工医学院学报,2004,16(3):277-278. 被引量：1
-
6买新连,朱海珍.奥沙利铂和大剂量5-Fu治疗晚期大肠癌的护理[J].中国社区医师（医学专业）,2008,10(12):126-126.
-
7翁洁,管丽莉,刘颂莲.奥沙利铂辅助治疗大肠癌疗效观察[J].医学临床研究,2005,22(4):571-572.
-
8潘春霞,张桂敏,张捷,时淑珍.FOLFOX方案治疗晚期大肠癌及胃癌近期疗效观察[J].医师进修杂志,2005,28(12):43-44. 被引量：1
-
9孙建伟,贾玲,林人龙,杨净瑜,刘春生.奥沙利铂联合氟尿嘧啶、亚叶酸钙治疗进展期大肠癌[J].中国癌症杂志,2002,12(1):89-89. 被引量：6
-
10宇文利霞,孔应利,时绘绘.铂类抗癌药毒性及其与药物化学结构的关系[J].临床合理用药杂志,2017,10(6):107-108. 被引量：7
